Ossium Health
San Francisco, US · Founded 2016 · Delaware corporation · 7 known investors
Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.
Founders & leadership
Ossium Health was founded in 2016 by Kevin Caldwell, Dr. Woods, Sebastian Giwa, and Erik Woods.
Board
Investors · 7
Reported raises · per SEC filings
Form D private placements$10.4M disclosed across 1 round · 2018
▶$10.4MraisedMay 2018 · 12 investors · BiotechnologyRule 506(b)
- William TrenchardDirector
- Kevin CaldwellExecutive Officer, Director
- Erik WoodsExecutive Officer, Director
- Sebastian GiwaDirector
- Thomas CycyotaDirector
- Offering amount
- $10.4M
- Amount sold
- $10.4M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Companies competing with Ossium Health for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $248.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $224.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $272.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $239.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ossium Health do?
- Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms. The company operates as a clinical-stage biotech firm manufacturing and distributing cellular therapeutics for patients with organ and tissue diseases.
- Who founded Ossium Health?
- Ossium Health was founded by Kevin Caldwell, Dr. Woods, Sebastian Giwa, Erik Woods in 2016.
- Who are Ossium Health's investors?
- Ossium Health's investors include Hemisphere Ventures LLC, Manta Ray Ventures, Vivo Capital, XYZ Venture Capital, FemHealth Ventures, First Round Capital, Village Global.
- How much funding has Ossium Health raised?
- Ossium Health has disclosed $10.4M raised across 1 round.
- Where is Ossium Health headquartered?
- Ossium Health is headquartered in San Francisco, US.